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Perth, Western Australia, AustraliaABSTRACT
The World Health Organization, World Heart Federation, and other organizations recommend comprehensive
control programs for rheumatic fever (RF) and rheumatic heart disease (RHD). However, advice on
components of control programs are simple lists, with little guidance on program structure or priorities. In
particular, there are limited recommendations on “stepwise” implementation and few guidelines on which
program components should take temporal priority. An evidence-based framework for describing,
prioritizing, and implementing comprehensive RF/RHD control programs is needed. A literature review of
existing RF/RHD control program recommendations generated a list of program components. Descriptions
and analysis of RF/RHD control programs informed temporal prioritizing of component parts. Relevant
programmatic research from other vertical disease control programs was reviewed for generalizable
implementation experiences. Twenty-ﬁve individual components of comprehensive RF/RHD control
programs were identiﬁed. These fell into “baseline” program requirements (including burden of disease
data, treatment guidelines, and human resources) and requirements for providing primary, secondary, and
tertiary interventions. Primordial prevention and research priorities were overarching themes. These
components were developed into a conceptual framework schema. Existing literature contains valuable
lessons on the design and implementation of comprehensive RF/RHD control programs. Fashioning these
guidelines and programmatic experiences into a conceptual framework schema beneﬁts clinicians, policy
makers, and RHD advocates.From the Telethon Institute
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CC BY-NC-ND license.By the most conservative estimates, more than 15.6
million people globally suffer from rheumatic heart disease
(RDH) and 233,000 die of the disease each year around the
world [1]. RHD is precipitated by group A streptococcal
infection, progressing to the post-infectious syndrome of
rheumatic fever (RF) in some people. Approximately 60%
of these cases of RF induce the persistent valvular damage
of RHD [2]. RF/RHD are endemic in most low- and
middle-income countries and in some socioeconomically
deprived groups in high-resource settings [1]. RF/RHD
disproportionately affect young people and constitute a
signiﬁcant economic burden for low-income families,
contribute to maternal mortality, and further strain already
overstretched health systems [3e5].
RF/RHD have been successfully controlled in a number
of settings through the implementation of register-based
control programs [6e9]. This register-based approach to
RF/RHD control has been recommended by the World
Health Organization (WHO) and World Heart Federation
(WHF) for many years [10e12]. Most control programs
are “comprehensive” in that they attempt to intervene at
multiple points along the protracted etiological pathway of
RF/RHD [13,14]. (Although poorly deﬁned, the concept of
“comprehensive RF/RHD control programs” functionally
reﬂects a spectrum of approaches with variable weighting
of primary and secondary approaches. [14e16].)GLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 241-246Guidelines for the activities and components of
comprehensive RF/RHD control programs have historically
been simple lists [11,12]. These lists have tended to have
few details on program structure or priorities. A stepwise
approach to implementation is recommended, though little
guidance about initial steps or program structure has been
published to date [12,17]. This has spurred concerns that
complex interventions—including surgery and active case
ﬁnding with echocardiography—could occur in isolation,
without ensuring program capacity to deliver other
essential services, or at the expense of cost effectiveness
[14,18e21]. Need for a “preliminary protocol with basic
components” for stepwise implementation has already been
identiﬁed [9].
A new wave of RF/RHD control programs is likely in
the wake of pending global burden of disease data, renewed
international advocacy, and the expansion of early diag-
nosis through echocardiographic screening [16,22,23]. Yet,
among the greatest challenges in RF/RHD disease control is
putting proven approaches into practice [16,23]. An
evidence-based framework for describing, designing,
implementing, and evaluating comprehensive RF/RHD
control programs would maximize the beneﬁt of new and
reinvigorated efforts in disease control. A conceptual
framework may also provide a common foundation for
international collaboration and implementation research.241
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242This paper collates published recommendations about
RF/RHD control programs. Core components are identiﬁed
and arranged in an attempt to reﬂect relative complexity
and priority. The conceptual framework is intended as a
starting point for programmatic discussions by clinicians,
managers, policy makers, and government and funding
agencies. This ﬁrst iteration will be open to revision as new
evidence and programmatic experience emerges.METHODS
Benchmark World Health Organization and World Heart
Federation guidelines on RF/RHD control programs were
reviewed to inform search strategy. Current recommen-
dations have largely appeared in institutional documents,
limiting utility of a systematic peer-reviewed approach.
Countries with existing RF/RHD guidelines—drawn from
World Heart Federation’s RHDNet—were reviewed to
identify recommendations applicable to other settings.
Bibliographic review and a snowball approach were used to
identify other program reviews and recommendations.
Listed recommendations for RF/RHD control programs
were coded to identify common themes. Program reports that
did not make speciﬁc recommendations for other initiativesRes
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BPG, benzathine penicillin G; GAS, group A streptococcal; RFwere excluded from formal thematic analysis. Content from
these papers was used qualitatively to inform prioritization
and to identify potentially under-represented areas. A number
of contemporary areas were speciﬁcally reviewed: tertiary
interventions; active case ﬁnding via echocardiography; and
primordial prevention.
Themes identiﬁed from the literature review were
condensed into a list of components of comprehensive RF/
RHD control programs. The list was arranged into domains
representing the classic primordial, primary, secondary,
and tertiary approach to RF/RHD control (Fig. 1). Within
each domain, components were arranged in order of po-
tential priority or temporal sequence based on narrative
descriptions of program implementation.RESULTS
Four institutions have published recommendations for
comprehensive control programs [10,12,24e26]. Five
more papers identiﬁed speciﬁc program recommendations
applicable to other initiatives [17,27e30]. One book
chapter was identiﬁed and excluded from formal analysis,
because the depth and speciﬁcity of the recommendations
exceeded the requirements for this review [31]. Thus,earch
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9 core sources were used to generate a list of compre-
hensive program components. A much larger number of
papers described or reviewed existing programs, but they
did not make explicit recommendations directly relevant to
other programs [6,9,21,32e45]. These papers were used
to generate original recommendations on program com-
ponents and to inform priority setting.
Twenty-ﬁve individual components of comprehensive
RF/RHD control programs were identiﬁed (Fig. 1). Do-
mains included baseline components and requirements for
providing primary, secondary, and tertiary interventions.
Primordial prevention and research were identiﬁed as
overarching themes.DISCUSSION
Research, advocacy, and funding are generating renewed
momentum for the global control of RF/RHD [16,23].
These developments may encourage countries to develop
new RF/RHD control programs, revive previous efforts, or
evaluate existing programs. A systemic approach to disease
control programs would maximize clinical beneﬁt for in-
dividuals, reduce inefﬁciency, and provide opportunities
for global knowledge sharing.
The conceptual framework is structured to provide a
visual overview of priorities, moving from left to right
across the page (Fig. 1). For example, a new RF/RHD
program should address burden of disease data, govern-
ment engagement, community education, register devel-
opment, and medical management of established cases as
initial goals. Programs will necessarily be adaptable to local
settings and may elect to have slightly different areas of
long-term focus. However, a singular focus on advanced
components (e.g., active case ﬁnding of sore throats,
echocardiographic screening, or interventional services)
without attention to interim steps is to be discouraged.Inclusions in the framework
Many components of RF/RHD control programs are the
subject of widespread agreement, including community
education, development of a register, and training health
workers. However, some areas have been less well
explored, necessitating a brief rationale for inclusion:
Primary prevention and active case ﬁnding for
group A streptococcal pharyngitis Treatment of
symptomatic group A streptococcal pharyngitis infections
presenting to clinicians is broadly accepted and encouraged
[41,46,47]. There is less clarity around active case ﬁndings
via sore throat clinics in schools, which are widely adopted
in some settings and eschewed in others [15,42,48].
Detailed exploration of this issue is outside the scope of
this paper. Sore throat clinics are included in the
framework as an advanced component of potential
relevance in some settings.GLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 241-246Active case ﬁnding with echocardiographic
screening The clinical beneﬁts of active case ﬁndings
via echocardiographic screening is yet to be fully explored
[21]. However, the theoretical beneﬁt is dependent upon a
functional register-based program, complete with access to
benzathine penicillin G and case follow-up [21]. The
conceptual framework helps to illustrate this dependency
to funders and policy makers, ensuring that screening
programs are coupled with prerequisite components of
service delivery.
Tertiary components The framework includes a more
detailed approach to tertiary intervention—medical man-
agement, anticoagulation, surgical or endovascular ap-
proaches—than existing program recommendations. The
historic disconnect between comprehensive programs and
tertiary interventions may reﬂect lack of access to open and
endovascular procedures. However, access to interventional
surgical services is increasing in many endemic regions and
should align closely with existing RHD programs [49].
Strong links between register-based programs and tertiary
services are likely to potentiate triage of candidates and
help support post-intervention follow-up. Interventional
options should not be delivered in isolation by local
providers, charitable groups, or overseas governments.
Isolated efforts risk diverting funds from more cost-
effective preventative approaches or without ensuring
adequate mechanisms for follow-up [21,49].
Vaccine development Few RF/RHD control programs
in highly endemic settings will have the capacity for vac-
cine development activities. However, individual programs
can support vaccine development through advocacy to
governments and identifying endemic populations appro-
priate for clinical trials. This programmatic support is
critical for eventual vaccination development and delivery.
Driving the momentum for an RF/RHD vaccine is a shared
responsibility of control programs internationally.
Integration with primary care and health
systems Many existing program recommendations
include references to “integration,” primary care, or “existing
health care delivery systems” [10,27,29]. However, achieving
meaningful integration remains a challenge in most settings
[16]. Although “integration” is not a discrete block of
activities, it should be given explicit and conscious attention
during program planning [50]. Awaiting opportunities for
integration to emerge and pervade RF/RHD programs has
been historically insufﬁcient. Allocating time, funding, and
resources to create space for integration activities is critical.
Primordial prevention is an overarching, but often
underarticulated, theme of RF/RHD efforts. Population-
level prevention activities have fallen largely outside the
scope of traditional comprehensive control programs. An
array of complex socioeconomic factors appear to inﬂuence
manifestation of RF/RHD, including overcrowding, nutri-
tion, and health access [14,42]. Many others, particularly243
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244socioeconomic status and inequality, may also be
contributory factors. Although these issues may be difﬁcult
for control programs to address directly, program imple-
menters bring a unique perspective to the need for pri-
mordial intervention [51]. Policy advocacy is an important
role for RF/RHD control programs, particularly given the
relative contribution of socioeconomic conditions to dis-
ease burden [13]. Broadly strengthening the advocacy ca-
pacity of the RF/RHD community is critical for addressing
persistent neglect of the disease among decision makers
[52].
Research is a second overarching theme for RF/RHD
programs. A broad array of disease control questions
remain unanswered, including natural history of subclini-
cal carditis, the role of echo screening, program optimi-
zation, and the development of novel therapies [16]. Many
of these questions can only be answered in highly endemic
communities. Coupling research activities with a compre-
hensive service delivery program is more appropriate and
ethically defensible than stand-alone research projects are
[53]. Engagement in the research community also fosters
collaboration for clinicians and academics in remote and
low-resource settings. Maintaining a rigorous evidence base
for disease control efforts is a shared responsibility for all
register-based programs.Reﬁning the conceptual framework
Identifying best practices for RF/RHD control programs
require comparison and analysis of implementation expe-
riences. A large volume of this information already exists in
peer-reviewed literature. However, only some investigators
make explicit recommendations for improving existing
programs and very few make suggestions applicable to new
programs. These formal publications represent only a
fraction of program reports provided to governments and
external donors. Collating and analyzing this experiential
evidence base will be critical for advancing implementation
science [16,23].
The proposed conceptual framework provides a start-
ing point for knowledge sharing with a common set of
terminology. Calls for standardization of terms have been
longstanding [54]; some progress has been achieved in
simple disease categories and echocardiographic terms but
not in program implementation to date [11,55]. Capital-
izing on shared terms and structure, collaborative efforts to
build a more robust framework should be encouraged.
New components may be added; for example, a protocol
for managing anaphylaxis may be prioritized before de-
livery of secondary prophylaxis is commenced. Pooling
international service delivery experience will continue to
inform ongoing development of the framework. More
substantial program implementation recommendations
should be possible. Although “anticoagulation” is identiﬁed
as a conceptual framework component, there is no detail
on possible approaches, relative costs, compliance, or
clinical protocols. Exploring the substance of componentswithin the framework requires signiﬁcant development and
international collaboration.
A number of areas were consciously excluded from
this initial version of the framework. Prescriptive lists of
staff and equipment have been avoided at this stage (e.g.,
echo machines, sonographers, information pamphlets,
disease notiﬁcation forms), as these will depend on local
conditions. Development of a practical “program imple-
mentation handbook” may be a natural extension of the
framework in the future.Application of the conceptual framework
The conceptual framework is applicable to a number of
stakeholders in global RF/RHD control. For most, the
framework adds value through visual comprehensibility.
RF/RHD is a complex disease with unwieldy acronyms, a
protracted course, and multiple opportunities for inter-
vention. Few of the constituent groups needed for disease
control will be technical experts. Providing a concise
snapshot of control program activities enhances commu-
nication to all. Some stakeholders may identify speciﬁc
beneﬁts:
Governments and policy makers The framework may
simplify options for decisionmakers by offering guidance on
stepwise program intervention. In resource-limited settings,
staged rollout may be more politically and economically
feasible than de novo development of a complete program.
Governments should be encouraged to take any action
toward RF/RHD control, ideally ﬁrst-tier interventions,
with a plan to provide increasingly advanced services.
Donors and funders One of the challenges in securing
much-needed resources for RF/RHD is the breadth and
complexity of comprehensive programs. Without specialist
knowledge of the disease, donors may struggle to
understand how their contribution adds to program
delivery and prevention efforts. The conceptual framework
provides a common ground for funders and implementers
to take stock of a proposed program and agree on areas to
be strengthened. This approach may help to avoid
sequestration of funding for tertiary services, without
addressing basic needs such as benzathine penicillin G
supply.
Program reporting and evaluation template With
the expansion of comprehensive RF/RHD programs comes
increasing reporting and evaluation requirements. Without a
structured framework, critical program issues may be
overlooked. Encouraging programs to report on activities in
each of the program components would ensure that core
components were addressed and improve comparability
between programs. With improvements in the model, it may
be possible to develop an objective evaluation template
specifying gold-standard practice in each domain and
providing customized feedback to programs.GLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 241-246
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Program handbook The framework provides a broad
overview of activities and priorities in comprehensive
control programs. It provides no detail about how these
can best be achieved. Collating detailed implementation
experience—components of register-based programs,
technical speciﬁcations for echo screening programs—are
best addressed in an implementation handbook that
could be structured around the headings of the
conceptual framework.SUMMARY
Decades of global experience in the design and imple-
mentation of comprehensive RF/RHD control programs
already exist. The conceptual framework distills some of this
experience, and existing recommendations, into a concise
visual overview. Design, development, implementation, and
evaluation of programs beneﬁt from a strategic approach.
This standardized approach facilitates international collab-
oration, fostering efforts to achieve excellence in program
delivery. Evolution and development of the model is inevi-
table and encouraged; this ﬁrst iteration is designed to pro-
vide a foundation for policy makers, governments, donors,
researchers, and program implementers. Ultimately, a focus
on comprehensive control programs beneﬁts the millions of
people living with RHD.REFERENCES
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